XML 65 R39.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue Recognition (Tables)
12 Months Ended
Dec. 31, 2024
Disaggregation of Revenue [Line Items]  
Summary of Disaggregation of Revenues
The following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands):
Year Ended
December 31, 2024
Year Ended
December 31, 2023
Year Ended
December 31, 2022
U.S.Non U.S.TotalU.S.Non U.S.TotalU.S.Non U.S.Total
Product revenue, net
HEPLISAV-B$264,973 $3,457 $268,430 $213,295 $$213,295 $124,996 $941 $125,937 
CpG 1018 adjuvant587,708 587,708 
Total product revenue, net$264,973 $3,457 $268,430 $213,295 $$213,295 $124,996 $588,649 $713,645 
Other revenue8,642 174 8,816 17,650 1,339 18,989 8,774 264 9,038 
Total revenues$273,615 $3,631 $277,246 $230,945 $1,339 $232,284 $133,770 $588,913 $722,683 
HEPLISAV-B  
Disaggregation of Revenue [Line Items]  
Schedule of Revenues from Major Customers
The following table summarizes HEPLISAV-B product revenue from each of our three largest customers (as a percentage of total HEPLISAV-B net product revenue):
Year Ended
December 31,
202420232022
Largest customer30 %28 %21 %
Second largest customer21 %27 %17 %
Third largest customer19 %17 %16 %
Summary of Product Revenue Allowance and Reserve Categories
The following table summarizes balances and activities in HEPLISAV-B product revenue allowance and reserve categories (in thousands):
Balance at
Beginning of
Period
Provisions
related to current
period sales
Credit or payments
made during
the period
Adjustments related to prior periods
Balance
at End of
Period
Year ended December 31, 2024:
Accounts receivable reserves (1)
$7,011 $74,147 $(71,831)$(10)$9,317 
Revenue reserve accruals (2)
$21,004 $55,052 $(43,310)$(1,267)$31,479 
Year ended December 31, 2023:
Accounts receivable reserves (1)
$8,179 $55,604 $(54,143)$(2,629)$7,011 
Revenue reserve accruals (2)
$10,552 $46,062 $(38,207)$2,597 $21,004 
(1)Reserves are for chargebacks, discounts and other fees.
(2)Accruals are for returns, rebates and other fees.
CpG 1018 adjuvant  
Disaggregation of Revenue [Line Items]  
Summarizes balances and activities in our contract asset account The following table summarizes balances and activities in our contract asset account (in thousands):
 
Balance at
Beginning
of Period
Additions
Subtractions
Reclassification (2)
Balance
at End of
Period
Year ended December 31, 2024:
Contract asset, included in other current assets (1)
$1,389 $8,642 $(9,680)$$351 
Contract asset, included in other assets (long term)$71,307 $$$$71,307 
Year ended December 31, 2023:
Contract asset, included in other current assets$71,965 $17,650 $(16,919)$(71,307)$1,389 
Contract asset, included in other assets (long term)$$$$71,307 $71,307 
(1)The $0.4 million of contract asset is derived from our agreement with the DoD.
(2)The Clover contract asset was reclassified to long term assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. See Note 9 for further discussion.